These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 12771643)

  • 41. Intraperitoneal and subcutaneous pharmacokinetics of low molecular weight heparin in continuous ambulatory peritoneal dialysis patients.
    Sifil A; Mermut C; Yenicerioglu Y; Cavdar C; Gumustekin M; Celik A; Yuksel F; Camsari T
    Adv Perit Dial; 2003; 19():28-30. PubMed ID: 14763030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Corral E; Martín A; Solinís MA; Muñoz JL
    Clin Ther; 2005 Sep; 27(9):1444-51. PubMed ID: 16291417
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo.
    Wurm G; Tomancok B; Nussbaumer K; Adelwöhrer C; Holl K
    Clin Neurol Neurosurg; 2004 Mar; 106(2):97-103. PubMed ID: 15003298
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of subcutaneous enoxaparin compared to intravenous heparin and oral phenprocoumon in the setting of cardioversion--the ACE study (Anticoagulation in Cardioversion using Enoxaparin).
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Card Electrophysiol Rev; 2003 Dec; 7(4):382-6. PubMed ID: 15071260
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enoxaparin should be used cautiously in patients with end-stage renal disease.
    Kalus JS; Spencer AP
    Pharmacotherapy; 2001 Aug; 21(8):1015-6; author reply 1017-9. PubMed ID: 11718491
    [No Abstract]   [Full Text] [Related]  

  • 46. Seamless anticoagulation therapy utilizing enoxaparin for acute coronary syndromes: Measure or not, here it comes!
    Slepian MJ
    Catheter Cardiovasc Interv; 2004 Feb; 61(2):171-2. PubMed ID: 14755806
    [No Abstract]   [Full Text] [Related]  

  • 47. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
    Bui HT; Krisnaswami A; Le CU; Chan J; Shenoy BN
    Am J Cardiol; 2009 Nov; 104(10):1429-33. PubMed ID: 19892063
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The design of venous thromboembolism prophylaxis trials: is enoxaparin more effective than fondaparinux?
    Lalourcey L
    Int J Clin Pract; 2003 May; 57(4):289-94. PubMed ID: 12800460
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study.
    Zezos P; Papaioannou G; Nikolaidis N; Patsiaoura K; Papageorgiou A; Vassiliadis T; Giouleme O; Evgenidis N
    Aliment Pharmacol Ther; 2006 May; 23(10):1443-53. PubMed ID: 16669959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
    Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
    Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Once-daily enoxaparin in pediatric thromboembolism: a dose finding and pharmacodynamics/pharmacokinetics study.
    O'Brien SH; Lee H; Ritchey AK
    J Thromb Haemost; 2007 Sep; 5(9):1985-7. PubMed ID: 17596139
    [No Abstract]   [Full Text] [Related]  

  • 54. Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.
    Enyart JJ; Jones RJ
    Ann Pharmacother; 2005 Jun; 39(6):1002-7. PubMed ID: 15886295
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies.
    Brophy DF; Carr ME; Martin EJ; Venitz J; Gehr TW
    J Clin Pharmacol; 2006 Aug; 46(8):887-94. PubMed ID: 16855073
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
    Kruse MW; Lee JJ
    Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Venous thromboembolism prophylaxis conversion in nonsurgical inpatients.
    Carroll DN; Hudson EB
    Ann Pharmacother; 2003 Sep; 37(9):1194-6. PubMed ID: 12921498
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
    Tetri S; Hakala J; Juvela S; Saloheimo P; Pyhtinen J; Rusanen H; Savolainen ER; Hillbom M
    Thromb Res; 2008; 123(2):206-12. PubMed ID: 18420258
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Prevention of embolism in severely ill internal medicine patients. In heart failure it is better to use low molecular weight heparin].
    MMW Fortschr Med; 1999 Nov; 141(46):64. PubMed ID: 10795156
    [No Abstract]   [Full Text] [Related]  

  • 60. Self-monitoring of anticoagulation.
    Li Wan Po A
    Lancet; 2012 May; 379(9828):1788-9; author reply 1789. PubMed ID: 22579317
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.